September 17, 2021 09:05:55
- Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure
- Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant”
- Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure
- These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment
Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure (“BP”) over a 24-hour ambulatory period. The results, referred to as
“Statistically significant” by Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, inched the company closer to an eventual New Drug Application (“NDA”) (
https://cnw.fm/KKLod).
The study involved volunteers getting three doses of 150 mg of DehydraTECH CBD over 24 hours, spanning both sleep and wake cycles of activity. Participants coping with mild to moderate hypertension reported…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at
https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing
CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW?
Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]
CBDWire is part of the
InvestorBrandNetwork.